Fundraising September 15, 2024 – October 1, 2024 About fundraising

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a...

  • Main
  • 2018 / 08
  • A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a...

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

Davis, S. Lindsey, Eckhardt, S. Gail, Diamond, Jennifer R., Messersmith, Wells A., Dasari, Arvind, Weekes, Colin D., Lieu, Christopher H., Kane, Madeline, Choon Tan, Aik, Pitts, Todd M., Leong, Stephe
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Oncologist
DOI:
10.1634/theoncologist.2018-0315
Date:
August, 2018
File:
PDF, 344 KB
english, 2018
Conversion to is in progress
Conversion to is failed